154 related articles for article (PubMed ID: 37666993)
1. SELEX based aptamers with diagnostic and entry inhibitor therapeutic potential for SARS-CoV-2.
Halder S; Thakur A; Keshry SS; Jana P; Karothia D; Das Jana I; Acevedo O; Swain RK; Mondal A; Chattopadhyay S; Jayaprakash V; Dev A
Sci Rep; 2023 Sep; 13(1):14560. PubMed ID: 37666993
[TBL] [Abstract][Full Text] [Related]
2. DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach.
Silwal AP; Thennakoon SKS; Arya SP; Postema RM; Jahan R; Phuoc CMT; Tan X
Theranostics; 2022; 12(12):5522-5536. PubMed ID: 35910791
[No Abstract] [Full Text] [Related]
3. A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.
Kim W; Song ES; Lee SH; Yang SH; Cho J; Kim SJ
Sci Rep; 2024 Mar; 14(1):7516. PubMed ID: 38553521
[TBL] [Abstract][Full Text] [Related]
4. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
[TBL] [Abstract][Full Text] [Related]
5.
Chen Y; Yang X; Liu J; Zhang D; He J; Tang L; Li J; Xiang Q
Nucleosides Nucleotides Nucleic Acids; 2023; 42(2):105-118. PubMed ID: 35949145
[TBL] [Abstract][Full Text] [Related]
6. Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection.
Rahman MS; Han MJ; Kim SW; Kang SM; Kim BR; Kim H; Lee CJ; Noh JE; Kim H; Lee JO; Jang SK
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375202
[TBL] [Abstract][Full Text] [Related]
7. DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic.
Villa A; Brunialti E; Dellavedova J; Meda C; Rebecchi M; Conti M; Donnici L; De Francesco R; Reggiani A; Lionetti V; Ciana P
Pharmacol Res; 2022 Jan; 175():105982. PubMed ID: 34798263
[TBL] [Abstract][Full Text] [Related]
8. In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein.
Lin YC; Chen WY; Hwu ET; Hu WP
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628622
[TBL] [Abstract][Full Text] [Related]
9. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
10. Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.
Alves Ferreira-Bravo I; DeStefano JJ
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696413
[TBL] [Abstract][Full Text] [Related]
11.
Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
[TBL] [Abstract][Full Text] [Related]
12. Preventive treatment of coronavirus disease-2019 virus using coronavirus disease-2019-receptor-binding domain 1C aptamer by suppress the expression of angiotensin-converting enzyme 2 receptor.
Hameed NS; Arif IS; Al-Sudani BT
J Adv Pharm Technol Res; 2023; 14(3):185-190. PubMed ID: 37692001
[TBL] [Abstract][Full Text] [Related]
13. Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era.
Dzuvor CKO; Tettey EL; Danquah MK
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 May; 14(3):e1785. PubMed ID: 35238490
[TBL] [Abstract][Full Text] [Related]
14. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
Pourmand S; Zareei S; Shahlaei M; Moradi S
Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
[TBL] [Abstract][Full Text] [Related]
16. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
17. Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells.
Hattori T; Saito T; Okuya K; Takahashi Y; Miyamoto H; Kajihara M; Igarashi M; Takada A
Microbiol Spectr; 2022 Aug; 10(4):e0087022. PubMed ID: 35862965
[TBL] [Abstract][Full Text] [Related]
18. A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism*.
Schmitz A; Weber A; Bayin M; Breuers S; Fieberg V; Famulok M; Mayer G
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10279-10285. PubMed ID: 33683787
[TBL] [Abstract][Full Text] [Related]
19. Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction.
Kim YS; Kwon EB; Kim B; Chung HS; Choi G; Kim YH; Choi JG
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293371
[TBL] [Abstract][Full Text] [Related]
20. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
